Anil Chandraker to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Anil Chandraker has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.385
-
Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, Tchekmedyian V, Ruiz ES, Waldman AH, Schmults CD, Riella LV, Lizotte P, Paweletz CP, Chandraker AK, Murakami N, Silk AW. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2024 Mar 20; 42(9):1021-1030.
Score: 0.191
-
Heo S, Park Y, Lee N, Kim Y, Kim YN, Shin HS, Jung Y, Rim H, Rennke HG, Chandraker A. Lack of Efficacy and Safety of Eculizumab for Treatment of Antibody-Mediated Rejection Following Renal Transplantation. Transplant Proc. 2022 Oct; 54(8):2117-2124.
Score: 0.174
-
Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients. Ann Pharmacother. 2011 Sep; 45(9):e48.
Score: 0.020